Correct usage and recommended dosage of bimekizumab

Bimekizumab (Bimekizumab) usage and dosage vary based on the indication. For patients with plaque psoriasis, the recommended dose is 320 mg subcutaneously at weeks 0, 4, 8, 12 and 16, followed by injections every 8 weeks; for patients weighing more than 120 kg, injections of 320 mg every 4 weeks after week 16 may be considered to ensure efficacy. In patients with psoriatic arthritis, a regimen of 160 mg subcutaneously injected every 4 weeks is usually used. For patients with moderate to severe plaque psoriasis, the dosage regimen for plaque psoriasis can be adjusted accordingly.

In the treatment of non-radiographic axial spondylitis and ankylosing spondylitis, the recommended dose is 160 mg subcutaneously every4 weeks. This dose can effectively control the inflammatory response of the spine and sacroiliac joints, relieve pain and stiffness, and improve mobility and quality of life. For patients with hidradenitis suppurativa, the starting dose is 320 mg, injected at 0, 2, 4, 6, 8, 10, 12, 14 and 16 weeks, and then every 4 weeks to ensure continued effect of the drug.

When using bicizumab, patients need to pay attention to the injection site, storage conditions, and follow the treatment plan prescribed by the doctor. Keep the skin clean and avoid local irritation during the injection process, and cooperate with routine follow-up and laboratory examinations to evaluate the efficacy and monitor potential adverse reactions. Patients on long-term treatment should have their injection frequency adjusted based on symptom improvement and disease activity to maximize efficacy and ensure safety.

It is worth emphasizing that if patients experience an increased risk of infection or local injection reaction during use, they should promptly inform their doctor to adjust the medication strategy. Compliance with the correct usage and dosage regimen is the key to ensuring that bicizumab exerts its best anti-inflammatory effect. It is also an important part of patients' long-term disease management and improvement of their quality of life.

Reference materials:https://www.drugs.com/bimekizumab.html